CN111758867A - 一种含有重组人类生长素微胶囊的固体饮料及其制备方法 - Google Patents
一种含有重组人类生长素微胶囊的固体饮料及其制备方法 Download PDFInfo
- Publication number
- CN111758867A CN111758867A CN202010610178.3A CN202010610178A CN111758867A CN 111758867 A CN111758867 A CN 111758867A CN 202010610178 A CN202010610178 A CN 202010610178A CN 111758867 A CN111758867 A CN 111758867A
- Authority
- CN
- China
- Prior art keywords
- recombinant human
- solid beverage
- microcapsules
- parts
- human auxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229930192334 Auxin Natural products 0.000 title claims abstract description 78
- 239000002363 auxin Substances 0.000 title claims abstract description 78
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 title claims abstract description 78
- 239000003094 microcapsule Substances 0.000 title claims abstract description 56
- 235000013361 beverage Nutrition 0.000 title claims abstract description 50
- 239000007787 solid Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 16
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 16
- 238000002156 mixing Methods 0.000 claims abstract description 16
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 16
- 239000011710 vitamin D Substances 0.000 claims abstract description 16
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 16
- 229940046008 vitamin d Drugs 0.000 claims abstract description 16
- 238000005303 weighing Methods 0.000 claims abstract description 14
- 239000004227 calcium gluconate Substances 0.000 claims abstract description 11
- 229960004494 calcium gluconate Drugs 0.000 claims abstract description 11
- 235000013927 calcium gluconate Nutrition 0.000 claims abstract description 11
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims abstract description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004376 Sucralose Substances 0.000 claims abstract description 9
- 238000007873 sieving Methods 0.000 claims abstract description 9
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 9
- 235000019408 sucralose Nutrition 0.000 claims abstract description 9
- 239000005018 casein Substances 0.000 claims abstract description 8
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000021240 caseins Nutrition 0.000 claims abstract description 8
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 7
- 238000011049 filling Methods 0.000 claims abstract description 7
- 238000004806 packaging method and process Methods 0.000 claims abstract description 7
- 239000002131 composite material Substances 0.000 claims abstract description 6
- 229960004543 anhydrous citric acid Drugs 0.000 claims abstract description 5
- 235000013365 dairy product Nutrition 0.000 claims abstract description 5
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 5
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 5
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 5
- 239000000230 xanthan gum Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 16
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 11
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical group [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000012982 microporous membrane Substances 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 8
- 239000004925 Acrylic resin Substances 0.000 claims description 7
- 229920000178 Acrylic resin Polymers 0.000 claims description 7
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 7
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 7
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 7
- 235000021014 blueberries Nutrition 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 229910001870 ammonium persulfate Inorganic materials 0.000 claims description 5
- 239000003999 initiator Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 239000008055 phosphate buffer solution Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 abstract description 8
- 230000037118 bone strength Effects 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000003973 paint Substances 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 229960005069 calcium Drugs 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 102000018997 Growth Hormone Human genes 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 102000002265 Human Growth Hormone Human genes 0.000 description 3
- 108010000521 Human Growth Hormone Proteins 0.000 description 3
- 239000000854 Human Growth Hormone Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 208000013558 Developmental Bone disease Diseases 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
- A23L2/395—Dry compositions in a particular shape or form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
本发明公开了一种含有重组人类生长素微胶囊的固体饮料及其制备方法,涉及固体饮料技术领域。其技术要点是:一种含有重组人类生长素微胶囊的固体饮料,该固体饮料包括如下重量份数的组分:重组人类生长素微胶囊0.22‑3.35份;葡萄糖酸钙40‑60份;维生素D0.003‑0.005份;酪蛋白磷酸肽8‑12份;植脂末150‑230份;无水柠檬酸2.4‑3.6份;三氯蔗糖0.5‑0.8份;黄原胶7‑10份;复合香精13‑20份。其由制备步骤为:(1)过筛;(2)称料;(3)预混;(4)混合;(5)分装、充填;(6)包装、入库。本发明制备得到的固体饮料具有营养健康、提高骨骼强度的优点,并且通过对重组人类生长素进行包埋处理,使其能够被直接口服使用,依然具有高生物活性和稳定性的优点。
Description
技术领域
本发明涉及固体饮料技术领域,更具体地说,它涉及一种含有重组人类生长素微胶囊的固体饮料及其制备方法。
背景技术
1920年,人们发现了生长激素(humangrowthhormone,hGH)的存在,生长激素是腺垂体细胞分泌的蛋白质,是一种肽类激素,由191个氨基酸残基构成,相对分子质量为22124道尔顿。生长激素分子构造上具有4个α螺旋,使生长激素可以和其受体有良好结合。1958年,人们发现可以将人生长素用于治疗侏儒症,但是,由于当时仅仅能够从尸体的脑垂体中提取出人生长素,数量有限,难以保证临床用量,从而限制了其应用。1986年,波耶尔通过基因重组的技术成功的合成了重组人类生长素(recombinant human growth hormone,rhGH),其结构与人垂体分泌的生长激素完全相同,这样便实现了重组人类生长素的大规模生产和应用。
重组人类生长素是由氨基酸组成的多肽,由于它是一种蛋白质,口服后会被胃酸所水解或被蛋白酶所水解,通过水解成为越来越小的肽链,直到成氨基酸混合体,生物小活性被破坏。目前市场上还没有出现口服重组人类生长素制品,只能通过注射来起效。
因此,需要提出一种新的方案来解决上述问题。
发明内容
针对现有技术存在的不足,本发明的目的一在于提供一种含有重组人类生长素微胶囊的固体饮料,其具有能够直接口服、生物活性高和稳定性好的优点。
本发明的目的二在于提供一种含有重组人类生长素微胶囊的固体饮料的制备方法,其具有制备工艺简单、适合大规模化生产的优点。
为实现上述目的一,本发明提供了如下技术方案:
一种含有重组人类生长素微胶囊的固体饮料,该固体饮料含有百分之一至千分之一的重量比例量的重组人类生长素微胶囊。
通过采用上述技术方案,重组人类生长素是利用基因工程技术生产的基因工程制品,它与由人脑垂体提取得到的天然人生长素的结构和生理功能是完全相同的,它是由191个氨基酸组成的蛋白质,分子量为22000道尔顿。国内外大量研究资料证明。该蛋白质具有控制细胞、骨骼、肌肉成长以及能有效地激活细胞功能等多种生理功能。
重组人类生长素是由氨基酸组成的多肽,由于它是一种蛋白质,口服后会被胃酸所水解或被蛋白酶所水解,通过水解成为越来越小的肽链,直到成氨基酸混合体,生物小活性被破坏。本发明通过在固体饮料中加入重组人类生长素微胶囊,对重组人类生长素进行包埋处理,可将其运送到人体肠道内定点释放,然后发挥效果。
进一步优选为,所述重组人类生长素微胶囊由如下制备步骤获得:
S1,将甲基丙烯酸、丙烯酸甲酯和引发剂加入到氯仿中,形成膜材溶液;
S2,称取重组人类生长素原料药,采用pH=7.4的磷酸盐缓冲液将其配置成8-10mg/L的药物溶液;
S3,将药物溶液加入到膜材溶液中,搅拌后于压力下过微孔膜,得到混合液;
S4,将混合液中氯仿除去、离心、冻干,得到丙烯酸树脂包覆重组人类生长素微胶囊。
通过采用上述技术方案,本发明自制的膜材溶液,其为能在结肠附近(pH≥7)开始溶解的缓释肠溶薄膜包衣材料,在pH小于7的环境下不溶,能够很好的将重组人类生长素送到目标地然后缓慢释放药物活性效果,具有很高的稳定性。有别于有机溶剂包衣材料,本发明自制的膜材溶液具有分散体包衣膜抗水渗透性好、能耗低、安全环保等优点。
本发明采用自制的肠溶丙烯酸树脂为载体材料对重组人类生长素进行包埋处理,并快速膜搅拌而制备出粒径均一可控,药物包埋率高,突释率低,能够持续释放药效,药物活性较高的微胶囊。
进一步优选为,步骤S1中,所述引发剂采用过硫酸铵或过硫酸钾。
通过采用上述技术方案,过硫酸铵和过硫酸钾作为引发剂可促进甲基丙烯酸和丙烯酸甲酯共聚物在有机溶剂氯仿中反应得到膜材。
进一步优选为,步骤S3中,所述微孔膜的孔径为0.5-600μm。
通过采用上述技术方案,通过将混合的溶液通过微孔膜,以除去部分粒径较大的原材料和控制产物的粒径大小。
进一步优选为,该固体饮料包括如下重量份数的组分:
重组人类生长素微胶囊:0.22-3.35份;
葡萄糖酸钙:40-60份;
维生素D:0.003-0.005份;
酪蛋白磷酸肽:8-12份;
植脂末:150-230份;
无水柠檬酸:2.4-3.6份;
三氯蔗糖:0.5-0.8份;
黄原胶:7-10份;
复合香精:13-20份。
通过采用上述技术方案,葡萄糖酸钙主要起到食品的钙强化剂与营养剂作用,可以预防和治疗钙缺乏症,如骨质疏松、手足抽搐症、骨发育不全等。重组人类生长素微胶囊、葡萄糖酸钙、维生素D三者一起加入产生了协同促进作用,使得组合物的钙质吸收率大大提高。
酪蛋白磷酸肽是以牛乳酪蛋白为原料,通过生物技术制得的具有生物活性的多肽,能够有效促进人体对钙、铁、锌等二价矿物营养素的吸收和利用。维生素D摄入过量会对肾和骨造成的危害,若复配使用酪蛋白磷酸肽和维生素D,可使肠道中的钙保持在溶解状态,从而有效促进钙的吸收和利用。
进一步优选为,所述复合香精由优格味粉末香精、蓝莓香精和粉末鲜奶精按照重量比(2-8):2:1混合组成。
通过采用上述技术方案,采用优格味的粉末香精,以及蓝莓香精和鲜奶精复配制作成独特味道的复合香精,其既具有浓稠丰厚的酸奶味,又兼具浓郁纯正的蓝莓香气,留香更持久,且绿色健康,全面提升固体饮料的口感。
为实现上述目的二,本发明提供了如下技术方案:
一种含有重组人类生长素微胶囊的固体饮料的制备方法,包括以下步骤:
(1)过筛;(2)称料;(3)预混;(4)混合;(5)分装、充填;(6)包装、入库。
进一步优选为,步骤(1)中,过筛时采用20目筛。
通过采用上述技术方案,通过将各原料经过20目筛,其粒径控制在合适的粒径,混合时,各原料更容易混合均匀,冲泡时冲调性较好。
进一步优选为,步骤(3)中,预混时,将维生素D、三氯蔗糖与重组人类生长素微胶囊等量混合5-10min,得到预混料。
通过采用上述技术方案,在混合之前新通过预混,将维生素等微量元素与低聚肽粉混合,制成预混料,然后再与剩下的营养物质和载体等混合,制成组分分布均匀的固体饮料。
综上所述,与现有技术相比,本发明具有以下有益效果:
(1)本发明通过在固体饮料中加入重组人类生长素微胶囊、葡萄糖酸钙和维生素D,三者具有协同作用,使得固体饮料具有提高较高营养价值和提高骨骼强度的优点;
(2)本发明通过在固体饮料中加入重组人类生长素微胶囊,对重组人类生长素进行包埋处理,可将其运送到人体肠道内定点释放,然后发挥效果;
(3)本发明采用自制的肠溶丙烯酸树脂为载体材料对重组人类生长素进行包埋处理,并快速膜搅拌而制备出粒径均一可控,药物包埋率高,突释率低,能够持续释放药效,药物活性较高的微胶囊。
附图说明
图1为本发明中含有重组人类生长素微胶囊的固体饮料的制备工艺流程图。
具体实施方式
下面结合附图和实施例,对本发明进行详细描述。
实施例1:如图1,一种含有重组人类生长素微胶囊的固体饮料,各组分及其相应的重量份数如表1所示,并通过如下步骤制备获得:
(1)过筛:将各原料组分过20目筛,备用;
(2)称料:按照配方用量依次对原料进行称料,称料过程中,一人称料,一人复核;
(3)预混:将维生素D、三氯蔗糖与重组人类生长素微胶囊等量混合5min,得到预混料;
(4)混合:将预混料与葡萄糖酸钙、酪蛋白磷酸肽、植脂末、无水柠檬酸、复合香精、黄原胶和剩余的维生素D、三氯蔗糖混合30min;其中复合香精由重量比为2:1:1的优格味粉末香精、蓝莓香精和粉末鲜奶精混合而成;
(5)分装、充填:将混合均匀的成品进行充填,其按照每袋6g的标准进行充填;
(6)包装、入库:按照要求进行包装,然后质量部门对其进行检验,合格后入库。
本实施例中,重组人类生长素微胶囊由如下制备方法获得:
S1,将100g甲基丙烯酸、82g丙烯酸甲酯和1.1g过硫酸铵加入到500mL氯仿中,升温至80℃,反应1h后冷却至室温,形成膜材溶液;
S2,称取重组人类生长素原料药,效价1.5mg/amp,4.0IU/amp,采用pH=7.4的磷酸盐缓冲液将其配置成50mL、8mg/L的药物溶液;
S3,将步骤S2得到的药物溶液加入到步骤S1中的膜材溶液中,于300rpm转速下搅拌3min,于2000kPa的压力下压过400nm微孔膜装置,得到混合液;
S4,于30℃下旋蒸除去氯仿,以12000rpm的速度。4℃条件下,离心除去未被包覆的重组人类生长素,真空干燥48h后,得到丙烯酸树脂包覆重组人类生长素微胶囊。测试得到漆突释率为13%,包封率为98.6%,释放出的rhGH聚集体含量为1.1%,具有较高的生物活性和稳定性。
实施例2-6:一种含有重组人类生长素微胶囊的固体饮料,与实施例1的不同之处在于,各组分及其相应的重量份数如表1所示。
表1 实施例1-6中各组分及其重量份数
实施例7:一种含有重组人类生长素微胶囊的固体饮料,与实施例1的不同之处在于,该固体饮料通过如下步骤制备获得:
(1)过筛:将各原料组分过20目筛,备用;
(2)称料:按照配方用量依次对原料进行称料,称料过程中,一人称料,一人复核;
(3)预混:将维生素D、三氯蔗糖与重组人类生长素微胶囊等量混合10min,得到预混料;
(4)混合:将预混料与葡萄糖酸钙、酪蛋白磷酸肽、植脂末、无水柠檬酸、复合香精、黄原胶和剩余的维生素D、三氯蔗糖混合45min;其中复合香精由重量比为8:1:1的优格味粉末香精、蓝莓香精和粉末鲜奶精混合而成;
(5)分装、充填:将混合均匀的成品进行充填,其按照每袋6g的标准进行充填;
(6)包装、入库:按照要求进行包装,然后质量部门对其进行检验,合格后入库。
实施例8:一种含有重组人类生长素微胶囊的固体饮料,与实施例1的不同之处在于,本实施例中,重组人类生长素微胶囊由如下制备步骤获得:
S1,将200g甲基丙烯酸、165g丙烯酸甲酯和2.4g过硫酸铵加入到1000mL氯仿中,升温至80℃,反应1h后冷却至室温,形成膜材溶液;
S2,称取重组人类生长素原料药,效价1.5mg/amp,4.0IU/amp,采用pH=7.4的磷酸盐缓冲液将其配置成90mL、10mg/L的药物溶液;
S3,将步骤S2得到的药物溶液加入到步骤S1中的膜材溶液中,于300rpm转速下搅拌3min,于2000kPa的压力下压过100nm微孔膜装置,得到混合液;
S4,于30℃下旋蒸除去氯仿,以12000rpm的速度。4℃条件下,离心除去未被包覆的重组人类生长素,真空干燥48h后,得到丙烯酸树脂包覆重组人类生长素微胶囊。测试得到漆突释率为16%,包封率为97.9%,释放出的rhGH聚集体含量为1.8%,具有较高的生物活性和稳定性。
实施例9:一种含有重组人类生长素微胶囊的固体饮料,与实施例1的不同之处在于,本实施例中,重组人类生长素微胶囊由如下制备步骤获得:
S1,将100g甲基丙烯酸、82g丙烯酸甲酯和1.1g过硫酸钾加入到500mL氯仿中,升温至80℃,反应1h后冷却至室温,形成膜材溶液;
S2,称取重组人类生长素原料药,效价1.5mg/amp,4.0IU/amp,采用pH=7.4的磷酸盐缓冲液将其配置成50mL、10mg/L的药物溶液;
S3,将步骤S2得到的药物溶液加入到步骤S1中的膜材溶液中,于300rpm转速下搅拌3min,于2000kPa的压力下压过200nm微孔膜装置,得到混合液;
S4,于30℃下旋蒸除去氯仿,以12000rpm的速度。4℃条件下,离心除去未被包覆的重组人类生长素,真空干燥48h后,得到丙烯酸树脂包覆重组人类生长素微胶囊。测试得到漆突释率为14%,包封率为98.4%,释放出的rhGH聚集体含量为1.2%,具有较高的生物活性和稳定性。
对比例1:一种固体饮料,与实施例1的不同之处在于,未加入重组人类生长素微胶囊。
对比例2:一种固体饮料,与实施例1的不同之处在于,采用重组人类生长素替代重组人类生长素微胶囊。
对比例3:一种固体饮料,与实施例1的不同之处在于,未加入葡萄糖酸钙。
对比例4:一种固体饮料,与实施例1的不同之处在于,未加入维生素D。
对比例5:一种固体饮料,与实施例1的不同之处在于,未加入重组人类生长素、葡萄糖酸钙和维生素D。
性能测试
测试对象:选取同一地区、年龄在45-55岁且男女各一半的志愿者,共900名,平均分为9组,每组100人。
测试方法:第1-7组分别饮用实施例1-7制得的含有重组人类生长素微胶囊固体饮料,第8-9组分别饮用对比例1-2中制得的固体饮料,一周饮用3次,共饮用3个月后测试每组志愿者的骨密度。测试结果计入表2中。
测试结果:T值为相对值,正常参考值在-1到+1之间,低于-2.5时为不正常且为骨质疏松。由表2中测试数据可知,实施例1-7中的志愿者T值均低于-1,当连续饮用3个月含有重组人类生长素微胶囊的固体饮料后,T值增大且处在正常范围内。对比例1-4中志愿者的T值均略有变高,对比例5中志愿者的T值则变得更小。说明本发明制备的固体饮料,采用重组人类生长素微胶囊为主要成分,并辅以葡萄糖酸钙和维生素D,其具有营养健康和提高骨骼强度的优点。
表2 性能测试结果
以上所述仅是本发明的优选实施方式,本发明的保护范围并不仅局限于上述实施例,凡属于本发明思路下的技术方案均属于本发明的保护范围。应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理前提下的若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (9)
1.一种含有重组人类生长素微胶囊的固体饮料,其特征在于,该固体饮料含有百分之一至千分之一的重量比例量的重组人类生长素微胶囊。
2.根据权利要求1所述的含有重组人类生长素微胶囊的固体饮料,其特征在于,所述重组人类生长素微胶囊由如下制备步骤获得:
S1,将甲基丙烯酸、丙烯酸甲酯和引发剂加入到氯仿中,形成膜材溶液;
S2,称取重组人类生长素原料药,采用pH=7.4的磷酸盐缓冲液将其配置成8-10mg/L的药物溶液;
S3,将药物溶液加入到膜材溶液中,搅拌后于压力下过微孔膜,得到混合液;
S4,将混合液中氯仿除去、离心、冻干,得到丙烯酸树脂包覆重组人类生长素微胶囊。
3.根据权利要求2所述的含有重组人类生长素微胶囊的固体饮料,其特征在于,步骤S1中,所述引发剂采用过硫酸铵或过硫酸钾。
4.根据权利要求2所述的含有重组人类生长素微胶囊的固体饮料,其特征在于,步骤S3中,所述微孔膜的孔径为0.5-600μm。
5.根据权利要求1所述的含有重组人类生长素微胶囊的固体饮料,其特征在于,该固体饮料包括如下重量份数的组分:
重组人类生长素微胶囊:0.22-3.35份;
葡萄糖酸钙:40-60份;
维生素D:0.003-0.005份;
酪蛋白磷酸肽:8-12份;
植脂末:150-230份;
无水柠檬酸:2.4-3.6份;
三氯蔗糖:0.5-0.8份;
黄原胶:7-10份;
复合香精:13-20份。
6.根据权利要求5所述的含有重组人类生长素微胶囊的固体饮料,其特征在于,所述复合香精由优格味粉末香精、蓝莓香精和粉末鲜奶精按照重量比(2-8):2:1混合组成。
7.根据权利要求5-6任一所述的含有重组人类生长素微胶囊的固体饮料的制备方法,其特征在于,包括以下步骤:
(1)过筛;(2)称料;(3)预混;(4)混合;(5)分装、充填;(6)包装、入库。
8.根据权利要求8所述的含有重组人类生长素微胶囊的固体饮料的制备方法,其特征在于,步骤(1)中,过筛时采用20目筛。
9.根据权利要求8所述含有重组人类生长素微胶囊的固体饮料的制备方法,其特征在于,步骤(3)中,预混时,将维生素D、三氯蔗糖与重组人类生长素微胶囊等量混合5-10min,得到预混料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010610178.3A CN111758867A (zh) | 2020-06-29 | 2020-06-29 | 一种含有重组人类生长素微胶囊的固体饮料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010610178.3A CN111758867A (zh) | 2020-06-29 | 2020-06-29 | 一种含有重组人类生长素微胶囊的固体饮料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111758867A true CN111758867A (zh) | 2020-10-13 |
Family
ID=72724106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010610178.3A Withdrawn CN111758867A (zh) | 2020-06-29 | 2020-06-29 | 一种含有重组人类生长素微胶囊的固体饮料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111758867A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112998101A (zh) * | 2021-04-20 | 2021-06-22 | 上海舒泽生物科技研究所 | 一种人体衰老kat7基因的抑制剂固体饮料及其制备方法 |
-
2020
- 2020-06-29 CN CN202010610178.3A patent/CN111758867A/zh not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
中国人大网: "《中华人民共和国食品安全法》", 7 January 2019 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112998101A (zh) * | 2021-04-20 | 2021-06-22 | 上海舒泽生物科技研究所 | 一种人体衰老kat7基因的抑制剂固体饮料及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9943485B2 (en) | Bioactive compounds protection method and compositions containing the same | |
JP6229188B2 (ja) | 生体材料のための安定化組成物 | |
JP4463109B2 (ja) | 栄養補助食品および水生動物の給餌方法 | |
TWI705766B (zh) | 特殊膳食用乾穩定益生菌組合物及其製備方法 | |
CN102125179B (zh) | 适用于乳仔猪的软胶囊营养补剂及其制备方法 | |
WO2006082824A1 (ja) | マトリックス型腸溶性・徐放性組成物 | |
EP1514553B1 (en) | Lactic acid bacteria powder double-coated using protein and polysaccharide and method preparing the same and a dosage form thereof | |
JP2019503707A (ja) | 糖類を全くまたはほとんど含有しない安定した乾燥組成物 | |
CN111494601B (zh) | 一种过瘤胃的肠溶性抗菌肽颗粒及制备方法 | |
JPS63501403A (ja) | こぶ胃で安定なペレット | |
KR100429495B1 (ko) | 단백질 및 다당류를 이용한 이중코팅 유산균 원말의제조방법 | |
CN101006829A (zh) | 高分子材料包裹的水产饲料添加剂 | |
EP4223137A1 (en) | Whey protein composition, and preparation method therefor and use thereof | |
CN1994133A (zh) | 胶原蛋白肽在食品中的应用方法 | |
CN110810517A (zh) | 一种多联益生菌固体饮料及其制备方法 | |
CN110786520A (zh) | 胶原蛋白钙肽粉及其制备方法 | |
CN111758867A (zh) | 一种含有重组人类生长素微胶囊的固体饮料及其制备方法 | |
US8828421B2 (en) | Method for encapsulation of orally ingested materials to alter the site of digestion, site of action, or stability | |
CN104351938A (zh) | 一种食品级肠溶性微胶囊的制备方法 | |
CN109527238A (zh) | 一种肠溶性复合微生态制剂的乳猪饲料的制备方法 | |
CN110903981A (zh) | 一种乳杆菌活菌保藏的方法及其活菌制剂 | |
CN103535462A (zh) | 一种微胶囊加碘茯砖茶及其制作工艺 | |
CN110367409A (zh) | 一种nfc果蔬汁的生产工艺 | |
CN118078761A (zh) | 一种拉沙洛西钠微丸及其制备方法 | |
WO2019090093A1 (en) | Composition containing viable microorganisms and methods of making |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20201013 |
|
WW01 | Invention patent application withdrawn after publication |